An interventional study of Balloon expandable TAVI in Symptomatic Severe Aortic Stenosis, sponsored by Abbott Medical Devices. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Aortic Valve Stenosis by Abbott — 4 open to participants now, 9 under way, none of them phase 3. Aortic Valve Stenosis · Abbott.
Among the 26 studies in Aortic Valve Stenosis by Abbott, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 with no phase, and was the 23rd registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →4 of the 26 studies in Aortic Valve Stenosis by Abbott are open now, in 12 countries. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Japan
Ages 18–100
Abbott Medical Devices · Sites in Australia, France, Germany and 8 more countries
Ages 18–100
Abbott Medical Devices · Sites in United States, Australia, Belgium and 10 more countries
Ages 18+
Abbott Medical Devices · Sites in Australia, France, Germany and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
This study's enrollment of 8 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 177 across the 20 interventional studies, 215 across the 6 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Abbott Medical Devices, one of the names counted as Abbott. Under that name alone:
Abbott Medical Devices is the lead sponsor of 541 studies on the registry; 34 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.
3 of the studies in Aortic Valve Stenosis by Abbott that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT07082426Abbott Medical DevicesEarly System Experience With the Abbott Balloon-expandable TAVI System: First-In-Human Study | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Aortic Valve Stenosis by Abbott, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Early System Experience with the Abbott Balloon-expandable TAVI System
The Early System Experience with the Abbott's balloon-expandable TAVI System first-in-human study ('EASE study') will evaluate preliminary clinical evidence on the safety and feasibility of the Abbott's balloon-expandable TAVI system for the treatment of patients with symptomatic severe aortic valve stenosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Balloon expandable TAVI
Prospective, single-arm, multi-center early experience study.
Technical Success
Successful access, delivery of the Abbott BE TAVI valve, and retrieval of the delivery system.
Time frame: Post procedure
Device success
Intended performance of the valve
Time frame: 30 days
Started Nov 2024 (actual). Primary completion is estimated for Aug 2027, 33 months after the start.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 33 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.